Entera Bio Stock Revenue
| ENTX Stock | USD 1.61 0.06 3.59% |
Entera Bio fundamentals help investors to digest information that contributes to Entera Bio's financial success or failures. It also enables traders to predict the movement of Entera Stock. The fundamental analysis module provides a way to measure Entera Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Entera Bio stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 14 K | 13.3 K |
Entera | Revenue |
Entera Bio Company Revenue Analysis
Entera Bio's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Entera Bio Revenue | 14 K |
Most of Entera Bio's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Entera Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Entera
Projected quarterly revenue analysis of Entera Bio provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Entera Bio match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Entera Bio's stock price.
Entera Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Entera Bio is extremely important. It helps to project a fair market value of Entera Stock properly, considering its historical fundamentals such as Revenue. Since Entera Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Entera Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Entera Bio's interrelated accounts and indicators.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Entera Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Entera Bio reported 14 K of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Entera Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Entera Bio's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Entera Bio could also be used in its relative valuation, which is a method of valuing Entera Bio by comparing valuation metrics of similar companies.Entera Bio is currently under evaluation in revenue category among its peers.
Entera Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Entera Bio from analyzing Entera Bio's financial statements. These drivers represent accounts that assess Entera Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Entera Bio's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 26.0M | 19.9M | 73.7M | 21.0M | 17.4M | 16.5M | |
| Enterprise Value | 11.1M | 11.7M | 49.1M | 8.8M | 6.8M | 6.4M |
Entera Bio Institutional Holders
Institutional Holdings refers to the ownership stake in Entera Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Entera Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Entera Bio's value.| Shares | Hightower Advisors, Llc | 2024-03-31 | 0.0 | Two Sigma Securities, Llc | 2024-03-31 | 0.0 |
Entera Fundamentals
| Return On Equity | -1.45 | ||||
| Return On Asset | -0.71 | ||||
| Operating Margin | (71.93) % | ||||
| Current Valuation | 54.9 M | ||||
| Shares Outstanding | 36.83 M | ||||
| Shares Owned By Insiders | 19.01 % | ||||
| Shares Owned By Institutions | 18.93 % | ||||
| Number Of Shares Shorted | 44.15 K | ||||
| Price To Earning | 2.10 X | ||||
| Price To Book | 9.08 X | ||||
| Price To Sales | 621.31 X | ||||
| Revenue | 14 K | ||||
| Gross Profit | 33 K | ||||
| EBITDA | (8.8 M) | ||||
| Net Income | (8.89 M) | ||||
| Cash And Equivalents | 17.28 M | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 390 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 10.89 X | ||||
| Book Value Per Share | 0.18 X | ||||
| Cash Flow From Operations | (7.31 M) | ||||
| Short Ratio | 1.98 X | ||||
| Earnings Per Share | (0.26) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 17 | ||||
| Beta | 1.59 | ||||
| Market Capitalization | 61.51 M | ||||
| Total Asset | 11.77 M | ||||
| Retained Earnings | (104.39 M) | ||||
| Working Capital | 10.17 M | ||||
| Current Asset | 8.46 M | ||||
| Current Liabilities | 7.64 M | ||||
| Net Asset | 11.77 M |
About Entera Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Entera Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Entera Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Entera Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Entera Stock Analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.